Harnessing lentiviral vectors for in vivo gene therapy of liver metastases

Keywords

cancer immunotherapy / gene therapy / lentiviral vectors / liver metastasis

References

[1] Wang X, Ji Q, Yan X, et al. The impact of liver metastasis on anti-PD-1 monoclonal antibody monotherapy in advanced melanoma: analysis of five clinical studies. Front Oncol. 2020;10:546604.

[2] Kerzel T, Giacca G, Beretta S, et al. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell. 2023;41:1892-1910.e1810.

[3] Milani M, Annoni A, Moalli F, et al. Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med. 2019;11:eaav7325.

[4] Merlin S, Cannizzo ES, Borroni E, et al. A novel platform for immune tolerance induction in Hemophilia A mice. Mol Ther. 2017;25:1815-1830.

[5] Annoni A, Brown BD, Cantore A, Sergi LS, Naldini L, Roncarolo MG. In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood. 2009;114:5152-5161.

[6] Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423-431.

[7] Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94(Suppl 2):S195-207.

[8] Krown SE. Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma. J Interferon Cytokine Res. 1998;18:209-214.

[9] Benz R, Siciliano RD, Stussi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol. 2009;82:194-200.

[10] Agrawal B, Kumar R. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. World J Gastroenterol. 2016;22:5623-5626.

[11] Birocchi F, Cusimano M, Rossari F, et al. Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models. Sci Transl Med. 2022;14:eabl4106.

[12] Cesana D, Ranzani M, Volpin M, et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther. 2014;22:774-785.

[13] Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273-288.

[14] Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56.

[15] Siddiqi T, Maloney DG, Kenderian SS, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet. 2023;402:641-654.

[16] Escobar G, Moi D, Ranghetti A, et al. Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci Transl Med. 2014;6:217ra213.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.